Retinoic acid enhances the levels of IL-10 in TLR-stimulated B cells from patients with relapsing-remitting multiple sclerosis

J Neuroimmunol. 2015 Jan 15:278:11-8. doi: 10.1016/j.jneuroim.2014.11.019. Epub 2014 Nov 24.

Abstract

We have explored the beneficial effects of retinoic acid (RA) on B cells from multiple sclerosis (MS) patients. When co-stimulated via the toll-like receptors (TLRs) TLR9 and RP105, MS B cells secreted less of the anti-inflammatory cytokine interleukin 10 (IL-10) compared to B cells from healthy controls. Importantly, RA enhanced the secretion of IL-10 by MS-derived B cells without affecting the levels of the pro-inflammatory cytokine TNF-α. RA revealed the same ability to induce IL-10 as did interferon-β-1b (IFN-β-1b), and B-cells from patients treated with glatiramer acetate or IFN-β-1b still displayed the beneficial effects of RA on the IL-10/TNF-α ratio.

Keywords: B cells; IL-10; Multiple sclerosis; Retinoic acid; TLR; TNF-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD / pharmacology*
  • Antigens, CD19 / metabolism
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / metabolism
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Interleukin-10 / metabolism*
  • Keratolytic Agents / pharmacology*
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / pathology*
  • Peptides / pharmacology
  • Toll-Like Receptor 9 / metabolism
  • Tretinoin / pharmacology*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antigens, CD
  • Antigens, CD19
  • CD180 protein, human
  • Immunosuppressive Agents
  • Keratolytic Agents
  • Peptides
  • Toll-Like Receptor 9
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Tretinoin
  • Glatiramer Acetate